Cargando…

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types

An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Minghui, Yuan, Jing, Lv, Gang, Brown, Jacob, Jiang, Xiangxiang, Lu, Zhiqiang Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624452/
https://www.ncbi.nlm.nih.gov/pubmed/34834458
http://dx.doi.org/10.3390/jpm11111106
_version_ 1784606177303199744
author Li, Minghui
Yuan, Jing
Lv, Gang
Brown, Jacob
Jiang, Xiangxiang
Lu, Zhiqiang Kevin
author_facet Li, Minghui
Yuan, Jing
Lv, Gang
Brown, Jacob
Jiang, Xiangxiang
Lu, Zhiqiang Kevin
author_sort Li, Minghui
collection PubMed
description An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in the United States according to age and vaccine type. This study used the Vaccine Adverse Events Reporting System (VAERS) from 11 December 2020 to 13 August 2021. A population-based data mining approach was performed based on the reporting odds ratio (ROR). Adverse events of myocarditis and pericarditis following COVID-19 vaccination were rare, with an incidence rate of 5.98 (95% CI = 5.73–6.24) cases per million doses administered. The incidence rate was higher in adolescents and after the administration of the second dose of messenger RNA (mRNA) vaccines. Overall, two mRNA vaccines were significantly associated with increased risks for myocarditis/pericarditis (mRNA-1273 (Moderna): ROR = 2.91, 95% CI = 2.21–3.83; BNT162b2 (Pfizer–BioNTech): ROR = 5.37, 95% CI = 4.10–7.04) compared to all other vaccines from VAERS. The viral vector vaccine of Ad26.COV2.S (Janssen) was not associated with signals of myocarditis/pericarditis (ROR = 1.39; 95% CI = 0.99–1.97). This study found increased risks for myocarditis/pericarditis following mRNA COVID-19 vaccines. For patients at high risk for myocarditis/pericarditis or with myocardial injuries, the viral vector vaccine may be an alternative for consideration.
format Online
Article
Text
id pubmed-8624452
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86244522021-11-27 Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types Li, Minghui Yuan, Jing Lv, Gang Brown, Jacob Jiang, Xiangxiang Lu, Zhiqiang Kevin J Pers Med Article An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in the United States according to age and vaccine type. This study used the Vaccine Adverse Events Reporting System (VAERS) from 11 December 2020 to 13 August 2021. A population-based data mining approach was performed based on the reporting odds ratio (ROR). Adverse events of myocarditis and pericarditis following COVID-19 vaccination were rare, with an incidence rate of 5.98 (95% CI = 5.73–6.24) cases per million doses administered. The incidence rate was higher in adolescents and after the administration of the second dose of messenger RNA (mRNA) vaccines. Overall, two mRNA vaccines were significantly associated with increased risks for myocarditis/pericarditis (mRNA-1273 (Moderna): ROR = 2.91, 95% CI = 2.21–3.83; BNT162b2 (Pfizer–BioNTech): ROR = 5.37, 95% CI = 4.10–7.04) compared to all other vaccines from VAERS. The viral vector vaccine of Ad26.COV2.S (Janssen) was not associated with signals of myocarditis/pericarditis (ROR = 1.39; 95% CI = 0.99–1.97). This study found increased risks for myocarditis/pericarditis following mRNA COVID-19 vaccines. For patients at high risk for myocarditis/pericarditis or with myocardial injuries, the viral vector vaccine may be an alternative for consideration. MDPI 2021-10-28 /pmc/articles/PMC8624452/ /pubmed/34834458 http://dx.doi.org/10.3390/jpm11111106 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Minghui
Yuan, Jing
Lv, Gang
Brown, Jacob
Jiang, Xiangxiang
Lu, Zhiqiang Kevin
Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_full Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_fullStr Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_full_unstemmed Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_short Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
title_sort myocarditis and pericarditis following covid-19 vaccination: inequalities in age and vaccine types
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624452/
https://www.ncbi.nlm.nih.gov/pubmed/34834458
http://dx.doi.org/10.3390/jpm11111106
work_keys_str_mv AT liminghui myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes
AT yuanjing myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes
AT lvgang myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes
AT brownjacob myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes
AT jiangxiangxiang myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes
AT luzhiqiangkevin myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes